PETMED EXPRESS INC — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
PetMed Express reported Q1 FY2026 (ended June 30, 2026) net sales of $41.0M, down 19.9% from $51.2M YoY, driven by lower prescription medication sales despite stabilizing sequential trends. Net loss improved to $6.1M (–$0.28/share) from $34.2M (–$1.65/share) prior year, primarily due to absence of $27.3M goodwill/intangible impairment charges. Adjusted EBITDA worsened to –$3.4M from –$2.7M. Cash declined $8.3M to $13.1M; company announced a sale-leaseback transaction to strengthen balance sheet.
Why this rating
Revenue decline and negative Adjusted EBITDA are concerning, but balance-sheet improvement via sale-leaseback and cost reductions offset near-term alarm. At $46M market cap, $41M quarterly sales is ~87% annualized. Small absolute cash position ($13M) relative to company size warrants monitoring but not yet critical.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.